|
[1]
|
Ascierto, P.A., Fu, B. and Wei, H. (2021) IL-6 Modulation for COVID-19: The Right Patients at the Right Time. The Journal for ImmunoTherapy of Cancer, 9, e002285. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Hu, F., Song, D., Yan, Y., et al. (2021) IL-6 Regulates Autophagy and Chemotherapy Resistance by Promoting BECN1 Phosphoryla-tion. Nature Communications, 12, 3651. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Zhong, Q., Fang, Y., Lai, Q., et al. (2020) CPEB3 Inhibits Epithelial-Mesenchymal Transition by Disrupting the Crosstalk between Colorectal Cancer Cells and Tumor-Associated Macrophages via IL-6R/STAT3 Signaling. Journal of Experimental & Clinical Cancer Research, 39, 132. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Masjedi, A., Hashemi, V., Ho-jjat-Farsangi, M., et al. (2018) The Significant Role of Interleukin-6 and Its Signaling Pathway in the Immunopathogene-sis and Treatment of Breast Cancer. Biomedicine & Pharmacotherapy, 108, 1415- 1424. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
刘淑娟, 刘梦莹, 陈一涛, 等. 乳腺癌患者紫杉类药物治疗所致神经病理性疼痛与血清IL-6水平的相关性研究[J]. 中国临床新医学, 2022, 15(11): 1012-1016.
|
|
[6]
|
邢旭. 2型糖尿病患者血清sKlotho、NGAL、IL-6和IL-18表达及意义[J]. 检验医学与临床, 2022, 19(20): 2825- 2828+2832.
|
|
[7]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Johnson, D.E., Keefe, R.A. and Grandis, J.R. (2018) Targeting the IL-6/JAK/STAT3 Signalling Axis in Cancer. Nature Reviews Clinical Oncology, 15, 234-248. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Heink, S., Yogev, N., Garbers, C., et al. (2017) Trans-Presentation of IL-6 by Dendritic Cells Is Required for the Priming of Pathogenic T(H)17 Cells. Nature Immunology, 18, 74-85. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Wolf, J., Rose-John, S. and Garbers, C. (2014) Interleukin-6 and Its Receptors: A Highly Regulated and Dynamic System. Cytokine, 70, 11-20. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Scheller, J., Chalaris, A., Schmidt-Arras, D. and Rose-John, S. (2011) The Pro- and Anti-Inflammatory Properties of the Cytokine Interleukin-6. Biochimica et Biophysica Acta, 1813, 878-888. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Wu, J., Gao, F.X., Wang, C., et al. (2019) IL-6 and IL-8 Se-creted by Tumour Cells Impair the Function of NK Cells via the STAT3 Pathway in Oesophageal Squamous Cell Carci-noma. Journal of Experimental & Clinical Cancer Research, 38, 321. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Chang, P.H., Pan, Y.P., Fan, C.W., et al. (2016) Pretreatment Se-rum Interleukin-1β, Interleukin-6, and Tumor Necrosis Factor-α Levels Predict the Progression of Colorectal Cancer. Cancer Medicine, 5, 426-433. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
De Simone, V., Franzè, E., Ronchetti, G., et al. (2015) Th17-Type Cyto-kines, IL-6 and TNF-α Synergistically Activate STAT3 and NF-κB to Promote Colorectal Cancer Cell Growth. Onco-gene, 34, 3493-3503. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Lee, J.W., Stone, M.L., Porrett, P.M., et al. (2019) Hepatocytes Direct the Formation of a Pro-Metastatic Niche in the Liver. Nature, 567, 249-252. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Lu, C.C., Kuo, H.C., Wang, F.S., Jou, M.H., Lee, K.C. and Chuang, J.H. (2014) Upregulation of TLRs and IL-6 as a Marker in Human Colorectal Cancer. International Journal of Molecular Sciences, 16, 159-177. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Lu, G., Tian, S., Sun, Y., et al. (2021) NEK9, a Novel Effector of IL-6/STAT3, Regulates Metastasis of Gastric Cancer by Targeting ARHGEF2 Phosphorylation. Theranostics, 11, 2460-2474. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Zhang, X., Hu, F., Li, G., et al. (2018) Human Colorectal Cancer-Derived Mesenchymal Stem Cells Promote Colorectal Cancer Progression through IL-6/JAK2/STAT3 Signaling. Cell Death & Disease, 9, 25. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Heichler, C., Scheibe, K., Schmied, A., et al. (2020) STAT3 Ac-tivation through IL-6/IL-11 in Cancer-Associated Fibroblasts Promotes Colorectal Tumour Development and Correlates with Poor Prognosis. Gut, 69, 1269-1282. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
李福青, 王红, 蒋海涛, 杜胜奇, 钟江利. TIM-3、STAT3、IL-6在结直肠腺癌中的表达及临床意义[J]. 中国老年学杂志, 2021, 41(20): 4386-4390.
|
|
[21]
|
Zeng, J., Tang, Z.H., Liu, S. and Guo, S.S. (2017) Clinicopathological Significance of Overexpression of Interleukin-6 in Colorectal Cancer. World Journal of Gastroenterology, 23, 1780-1786. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Hermunen, K., Soveri, L.M., Boisen, M.K., et al. (2020) Postoperative Serum CA19-9, YKL-40, CRP and IL-6 in Combination with CEA as Prognostic Markers for Recurrence and Survival in Colorectal Cancer. Acta Oncologica, 59, 1416-1423. [Google Scholar] [CrossRef]
|
|
[23]
|
Xu, J., Ye, Y., Zhang, H., et al. (2016) Diagnostic and Prognostic Value of Serum Interleukin-6 in Colorectal Cancer. Medicine (Baltimore), 95, e2502. [Google Scholar] [CrossRef]
|
|
[24]
|
Peltonen, R., Gramkow, M.H., Dehlendorff, C., et al. (2020) Elevated Serum YKL-40, IL-6, CRP, CEA, and CA19-9 Combined as a Prognostic Biomarker Panel after Resection of Colorectal Liver Metastases. PLOS ONE, 15, e0236569. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Thomsen, M., Kersten, C., Sorbye, H., et al. (2016) Interleu-kin-6 and C-Reactive Protein as Prognostic Biomarkers in metastatic Colorectal Cancer. Oncotarget, 7, 75013-75022. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Kim, S.H., Kim, J.W., Hwang, I.G., et al. (2019) Serum Bi-omarkers for Predicting Overall Survival and Early Mortality in Older Patients with Metastatic Solid Tumors. Journal of Geriatric Oncology, 10, 749-756. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Ebbing, E.A., van der Zalm, A.P., Steins, A., et al. (2019) Stro-mal-Derived Interleukin 6 Drives Epithelial-to-Mesen- chymal Transition and Therapy Resistance in Esophageal Adeno-carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 116, 2237-2242. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Yin, Y., Yao, S., Hu, Y., et al. (2017) The Im-mune-Microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-Derived IL6. Clinical Cancer Research, 23, 7375-7387. [Google Scholar] [CrossRef]
|
|
[29]
|
Yang, Z., Guo, L., Liu, D., et al. (2015) Acquisition of Re-sistance to Trastuzumab in Gastric Cancer Cells Is Associated with Activation of IL-6/STAT3/Jagged-1/Notch Positive Feedback Loop. Oncotarget, 6, 5072-5087. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Tian, D., Tian, M., Ma, Z.M., et al. (2020) Anesthetic Propofol Epi-genetically Regulates Breast Cancer Trastuzumab Resistance through IL-6/miR-149-5p Axis. Scientific Reports, 10, Arti-cle No. 8858. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Hara, M., Nagasaki, T., Shiga, K., et al. (2017) High Serum Levels of Interleukin-6 in Patients with Advanced or Metastatic Colorectal Cancer: The Effect on the Outcome and the Response to Chemotherapy plus Bevacizumab. Surgery Today, 47, 483-489. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Wu, H.H., Zhang, S., Bian, H., et al. (2015) Bevacizumab Regu-lates Cancer Cell Migration by Activation of STAT3. Asian Pacific Journal of Cancer Prevention, 16, 6501-6506. [Google Scholar] [CrossRef]
|
|
[33]
|
Li, J., Xu, J., Yan, X., et al. (2018) Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model. Medical Science Monitor, 24, 5501-5508. [Google Scholar] [CrossRef]
|
|
[34]
|
Zhong, H., Davis, A., Ouzounova, M., et al. (2016) A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. Can-cer Research, 76, 480-490. [Google Scholar] [CrossRef]
|
|
[35]
|
Kitamura, H., Ohno, Y., Toyoshima, Y., et al. (2017) Inter-leukin-6/STAT3 Signaling as a Promising Target to Improve the Efficacy of Cancer Immunotherapy. Cancer Science, 108, 1947-1952. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Dimitriou, F., Hogan, S., Menzies, A.M., et al. (2021) In-terleukin-6 Blockade for Prophylaxis and Management of Immune-Related Adverse Events in Cancer Immunotherapy. European Journal of Cancer, 157, 214-224. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Zhao, Y., Liu, X., Huo, M., et al. (2021) Cetuximab Enhances the Anti-Tumor Function of Macrophages in an IL-6 Dependent Manner. Life Sciences, 267, Article ID: 118953. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Keefe, R.A., Bhola, N.E., Lee, D.S., et al. (2020) Interleukin 6 Is Increased in Preclinical HNSCC Models of Acquired Cetuximab Resistance, but Is Not Required for Maintenance of Re-sistance. PLOS ONE, 15, e0227261. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Yuan, X., Zhang, L., Huang, Y., et al. (2021) Induction of In-terleukin-6 by Irradiation and Its Role in Epithelial Mesenchymal Transition and Radioresistance of Nasopharyngeal Car-cinoma Cells. Head & Neck, 43, 757-767. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Liu, X., Cao, X., Liu, C., et al. (2019) MTERFD1 Promotes Cell Growth and Irradiation Resistance in Colorectal Cancer by Upregulating Interleukin-6 and Interleukin-11. International Journal of Biological Sciences, 15, 2750-2762. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Kumari, N., Das, A. and Bhatt, A.N. (2020) Interleukin-6 Confers Ra-dio-Resistance by Inducing Akt-Mediated Glycolysis and Reducing Mitochondrial Damage in Cells. The Journal of Bio-chemistry, 167, 303-314. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Bell, B.I., Koduri, S., Salas Salinas, C., et al. (2019) Interleukin 6 Signaling Blockade Exacerbates Acute and Late Injury from Focal Intestinal Irradiation. International Journal of Radiation Oncol-ogy, Biology, Physics, 103, 719-727. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
马幸, 杨更光, 王万里. 血清IL-1β、IL-6、NO在结直肠癌患者手术前后水平变化及对预后的评估价值[J]. 中国卫生工程学, 2020, 19(2): 268-269.
|
|
[44]
|
Hinz, S., Tepel, J., Röder, C., et al. (2015) Profile of Serum Factors and Disseminated Tumor Cells before and after Radiofrequency Abla-tion Compared to Resection of Colorectal Liver Metastases—A Pilot Study. Anticancer Research, 35, 2961-2967.
|
|
[45]
|
Taniguchi, Y., Kurokawa, Y., Hagi, T., et al. (2019) Methylprednisolone Inhibits Tumor Growth and Peritoneal Seeding Induced by Surgical Stress and Postoperative Complications. Annals of Surgical Oncology, 26, 2831-2838. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Thomsen, M., Guren, M.G., Skovlund, E., et al. (2017) Health-Related Quality of Life in Patients with Metastatic Colorectal Cancer, Association with Systemic Inflammatory Response and RAS and BRAF Mutation Status. European Journal of Cancer, 81, 26-35. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Zaharuddin, L., Mokhtar, N.M., Nawawi, K.N.M. and Ali, R.A.R. (2019) A Randomized Double-Blind Placebo-Con- trolled Trial of Probiotics in Post-Surgical Colorectal Cancer. BMC Gastroenterology, 19, Article No. 131. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Saito, S., Suzuki, K., Yoshimoto, K., et al. (2022) Differences in the Strength of Inhibition of Interleukin-6 Signalling by Subcutaneous Sarilumab and Tocilizumab in Rheumatoid Arthri-tis Patients. Clinical and Experimental Rheumatology. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Rehman, M., Chattaraj, A., Neupane, K., et al. (2022) Effi-cacy and Safety of Regimens Used for the Treatment of Multicentric Castleman Disease: A Systematic Review. European Journal of Haematology, 109, 309-320. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Miller, C.L. and Madsen, J.C. (2022) Targeting IL-6 to Prevent Cardiac Al-lograft Rejection. American Journal of Transplantation, 22, 12-17. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Jordan, S.C., Choi, J., Kim, I., et al. (2017) Interleukin-6, a Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. Transplantation, 101, 32-44. [Google Scholar] [CrossRef]
|
|
[52]
|
Angevin, E., Tabernero, J., Elez, E., et al. (2014) A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Ad-vanced Solid Tumors. Clinical Cancer Research, 20, 2192-2204. [Google Scholar] [CrossRef]
|
|
[53]
|
Fogelman, D., Cubillo, A., García-Alfonso, P., et al. (2018) Randomized, Double-Blind, Phase Two Study of Ruxolitinib plus Regorafenib in Patients with Relapsed/Refractory Metastatic Colorectal Cancer. Cancer Medicine, 7, 5382- 5393. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Chung, Y.C., Ku, Y.L., Chiang, H.C., et al. (2021) Antibody to Interleukin-6 Receptor Inhibits in Vivo Growth of Human Colo-rectal Carcinoma Cell Xenografts. Anticancer Research, 41, 4907-4916. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Beyranvand Nejad, E., Labrie, C., van Elsas, M.J., et al. (2021) IL-6 Signaling in Macrophages Is Required for Immunotherapy-Driven Regression of Tumors. The Journal for Immuno-Therapy of Cancer, 9, e002460. [Google Scholar] [CrossRef] [PubMed]
|